Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

Tianmu Pharmaceutical released its half-year report on the evening of August 27. In the first half of 2026, it achieved operating revenue of 99.3547 million yuan, down 4.10 percent year on year, while total profit was 8.2842 million yuan, up 16.37 percent year on year. During the reporting period, the company's accounts receivable fell from 144 million yuan at the end of 2025 to 118 million yuan, and net cash flow from operating activities turned positive to 24.2866 million yuan. The company's pharmaceutical manufacturing segment developed steadily, revenue from medical technology services grew substantially, and sales of health products continued. In terms of capacity building, the wholly owned subsidiary Huangshan Tianmu's capacity improvement and technical renovation project has a total investment of about 100 million yuan. The first-phase civil works are basically complete and the project has entered the interior decoration and equipment installation stage. On product resumption, the former core product Pearl Eye Drops is in the preparation stage before GMP certification, and compound fresh bamboo decoction is advancing commissioned production. In new business, the Qingdao Simulation Medicine Center achieved revenue of 16.2289 million yuan in the first half of the year.

Tianmu Pharmaceutical announced that its controlling shareholder, Huilong Huaze, plans to transfer 24.3558 million unrestricted tradable shares, representing 20% of the company's total share capital, through a negotiated transfer by publicly soliciting a transferee. The transfer price will be no less than 22 yuan per share. Huilong Huaze currently holds a 29.99% stake in the company. If this transfer is completed, the company's controlling shareholder and actual controller may change.